Sigma Planning Corp’s Cognition Therapeutics CGTX Stock Holding History

Sigma Planning Corp’s Portfolio CGTX Stock Details CGTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$350K	Buy	364,765 +2,500	+0.7%	+$2.51K	0.01%	995
2026 Q2	$417K	Buy	362,265 +24,500	+7%	+$29K	0.01%	1001
2026 Q1	$257K	Buy	337,765 +121,600	+56%	+$142K	0.01%	1111
2025 Q4	$295K	Buy	216,165 +89,075	+70%	+$145K	0.01%	1039
2025 Q3	$172K	Sell	127,090 -20,900	-14%	-$28.5K	﹤0.01%	1233
2025 Q2	$45.8K	Sell	147,990 -460,400	-76%	-$155K	﹤0.01%	1232
2025 Q1	$256K	Sell	608,390 -6,100	-1%	-$3.58K	0.01%	1028
2024 Q4	$431K	Buy	614,490 +417,300	+212%	+$206K	0.01%	790
2024 Q3	$92.4K	Buy	197,190 +25,050	+15%	+$25.8K	﹤0.01%	1175
2024 Q2	$286K	Buy	172,140 +12,700	+8%	+$25.3K	0.01%	946
2024 Q1	$290K	Buy	159,440 +130,890	+458%	+$270K	0.01%	974
2023 Q4	$52.8K	Buy	+28,550	New	+$37.8K	﹤0.01%	825

Other funds holding CGTX

Davenport & Co Richmond, Virginia $19.9B AUM 12.67% 1-Year Est. Return

McAdam LLC Philadelphia, Pennsylvania $2.66B AUM 14.82% 1-Year Est. Return

Empirical Wealth Management Seattle, Washington $7.38B AUM 22.9% 1-Year Est. Return

Bangor Savings Bank Bangor, Maine $1.31B AUM 12.25% 1-Year Est. Return

Citizens Financial Group Providence, Rhode Island $8.58B AUM 20.32% 1-Year Est. Return

CWA Asset Management Group Naples, Florida $3.39B AUM 25.16% 1-Year Est. Return

Creative Planning Overland Park, Kansas $179B AUM 16.96% 1-Year Est. Return

Barry Investment Advisors New Bedford, Massachusetts $524M AUM 15.38% 1-Year Est. Return

RPGK

Retirement Planning Group (Kansas) Leawood, Kansas $4.01B AUM 11.74% 1-Year Est. Return

Chicago Partners Investment Group Chicago, Illinois $5.45B AUM 19.52% 1-Year Est. Return

Sigma Planning Corp's CGTX Position: Q3 2026 in Review

Sigma Planning Corp increased its Cognition Therapeutics (CGTX) stake by 0.69% in Q3 2026, buying an estimated $2.51K and bringing the position to 364,765 shares worth $350K. The position accounts for 0.01% of the portfolio, ranked #995.

Sigma Planning Corp first reported a position in CGTX in Q4 2023 and has held it in 12 quarters since. The position peaked at $431K in Q4 2024. 16 funds tracked by Wall St. Rank hold CGTX as of Q3 2026.

Sigma Planning Corp held 364,765 shares of Cognition Therapeutics worth $350K as of Q3 2026.
Sigma Planning Corp bought 2,500 Cognition Therapeutics shares in Q3 2026, an estimated $2.51K.
Cognition Therapeutics made up 0.01% of Sigma Planning Corp's portfolio in Q3 2026, its #995 holding.
Sigma Planning Corp first reported a position in Cognition Therapeutics in Q4 2023 and has held it in 12 quarters since.
Sigma Planning Corp's Cognition Therapeutics position peaked at $431K in Q4 2024.
16 funds tracked by Wall St. Rank held Cognition Therapeutics as of Q3 2026.

Based on Sigma Planning Corp's 13F filing for Q3 2026, filed 23 Oct 2026.